November 7-8, 20178:00 AM to 5:00 PM Daily
Connect With Us
Robert Kadlec, M.D.
Robert Kadlec, M.D.
Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services
Dr. Robert Kadlec is the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services (HHS). The ASPR serves as the Secretary’s principal advisor on matters related to public health emergencies, including bioterrorism. The office leads the nation in preventing, responding to and recovering from the adverse health effects of manmade and naturally occurring disasters and public health emergencies. As such, the office coordinates interagency activities between HHS, other federal agencies, and state and local officials responsible for emergency preparedness and the protection of the civilian population from public health emergencies.
Dr. Kadlec spent more than 20 years as a career officer and physician in the United States Air Force before retiring as a Colonel. Over the course of his career, he has held senior positions in the White House, the U.S. Senate, and the Department of Defense. Most recently, he served as the Deputy Staff Director to the Senate Select Committee on Intelligence.
Dr. Kadlec previously served as staff director for Senator Richard Burr’s subcommittee on bioterrorism and public health in the 109th Congress. In that capacity, he was instrumental in drafting the Pandemic and All-Hazard Preparedness Bill which was signed into law to improve the nation’s public health and medical preparedness and response capabilities for emergencies, whether deliberate, accidental, or natural.
Dr. Kadlec also served at the White House from 2002 to 2005 as director for biodefense on the Homeland Security Council, where he was responsible for conducting the biodefense end-to-end assessment, which culminated in drafting the National Biodefense Policy for the 21st Century. He served as Special Assistant to President George W. Bush for Biodefense Policy from 2007 to 2009.
Earlier in his career, he served as the Special Advisor for Counter proliferation Policy at the Office of the Secretary of Defense, where he assisted DOD efforts to counter chemical, biological, radiological, and nuclear (CBRN) threats in the wake of 9/11 and contributed to the FBI investigation of the anthrax letter attacks. He began his career as a flight surgeon for the 16th Special Operations Wing and subsequently served as a surgeon for the 24th Special Tactics Squadron and as Special Assistant to J-2 for Chemical and Biological Warfare at the Joint Special Operations Command. He was named U.S. Air Force Flight Surgeon of the Year in 1986.
Dr. Kadlec holds a bachelor’s degree from the United States Air Force Academy, a doctorate of medicine and a master’s degree in tropical medicine and hygiene from the Uniformed Services University of the Health Sciences, as well as a master’s degree in national security studies from Georgetown University.
Senator Tom Daschle
Senator Tom Daschle
Founder and CEO, The Daschle Group
Senator Daschle is the Founder and CEO of The Daschle Group, A Public Policy Advisory of Baker Donelson. The Daschle Group is a full-service strategic advisory firm that advises clients on a broad array of economic, policy and political issues.
Senator Daschle has participated in the development and debate of almost every major public policy issue of the last three decades. In 1978, he was elected to the US House of Representatives, where he served for eight years. In 1986, he was elected to the US Senate and was chosen as Senate Democratic Leader in 1994. Senator Daschle is one of the longest serving Senate Democratic leaders in history and one of only two to serve twice as both Majority and Minority Leader.
During his tenure, Senator Daschle navigated the Senate through some of its most historic economic and national security challenges. In 2003, he chronicled some of these experiences in his book, Like No Other Time: The 107th Congress and the Two Years That Changed America Forever. In the 2013 release of The US Senate: Fundamentals of American Government, Senator Daschle explores the inner workings of this important part of the legislative branch. In his latest book, Crisis Point, Senator Daschle and former Senate Majority Leader Trent Lott explore the political gridlock in Washington and offer their vision for moving the country forward.
Since leaving the Senate, Senator Daschle has remained an active and learned voice among policy-makers. As a well-known expert on health policy reform, he has written two books: Critical: What We Can Do About the Health-Care Crisis and Getting It Done: How Obama and Congress Finally Broke the Stalemate to Make Way for Health Care Reform.
Senator Daschle has also emerged as a leading thinker on climate change, food security and renewable energy policy. He serves on both advisory and governing boards of a number of corporate and non-profit organizations and currently co-chairs The Cuba Consortium, an organization dedicated to an improved relationship with the people of Cuba.
In 2007, Senator Daschle joined with former Majority Leaders George Mitchell, Bob Dole and Howard Baker to create the Bipartisan Policy Center, an organization dedicated to finding common ground on some of the pressing public policy challenges of our time. Senator Daschle is Chair of the Board of Directors at the Center for American Progress and Vice-Chair for the National Democratic Institute. He serves on the board of Edward M. Kennedy Institute and the LBJ Foundation. He also is a member of the Health Policy and Management Executive Council at the Harvard School of Public Health and the Council of Foreign Relations.
Born in Aberdeen, South Dakota, Senator Daschle attended South Dakota State University, graduating in 1969. He then served for three years as an intelligence officer in the US Air Force Strategic Command. Following his military service, he spent five years as an aide to South Dakota Senator James Abourezk. After leaving the Senate in 2005, Senator Daschle joined Alston & Bird LLP as a special policy advisor and then went on to work in the same role at DLA Piper before establishing The Daschle Group in 2014.
He is married to Linda Hall Daschle and has three children and six grandchildren.
Paul Stoffels, MD
Paul Stoffels, MD
Chief Scientific Officer, Johnson & Johnson
Paul Stoffels is a visionary leader who inspires and drives transformational innovation to bring years of life and quality of life to millions of people around the world.
As Chief Scientific Officer, Paul spearheads the Johnson & Johnson research and product pipeline by leading teams across the pharmaceutical, medical devices and consumer segments to discover and develop healthcare solutions to address unmet needs. He is also a pioneer in global public health and steers the company’s strategy to make innovative medicines and technologies accessible in the world’s most vulnerable communities and resource-poor settings.
Paul’s commitment to fueling innovation and finding the best science, wherever it exists, is the driving force behind the launch of Johnson & Johnson Innovation in 2013, which he now leads to foster science and technology through strategic partnerships, licensing and acquisitions.
Paul also oversees JJDC, the oldest corporate venture fund in the life science industry, has responsibility for safety of all products of the Johnson & Johnson Family of Companies worldwide, and is also member of the Johnson & Johnson Executive Committee and chairs the Johnson & Johnson R&D Management Committee.
Previously, in his role as Worldwide Chairman, Pharmaceuticals, Paul led the transformation of the pharmaceutical research and development pipeline for Janssen Pharmaceutical Companies of Johnson & Johnson, driving a fundamental shift in the R&D paradigm that is now a model in the industry for productivity and innovation. Under his leadership, Janssen rejuvenated its pipeline, launching multiple new medicines and making a difference for people all over the world.
Prior to this, Paul held various R&D leadership roles within the pharmaceutical sector of Johnson & Johnson. He joined Johnson & Johnson in 2002 with the acquisition of Virco and Tibotec, where he was Chief Executive Officer of Virco and as Chairman of Tibotec, and led the development of several breakthrough products for the treatment of HIV that helped to transform this devastating disease from a death sentence to a chronic and treatable condition.
Paul studied Medicine at the University of Diepenbeek and the University of Antwerp in Belgium and Infectious Diseases and Tropical Medicine at the Institute of Tropical Medicine in Antwerp, Belgium. He began his career as a physician in Africa, focusing on HIV and tropical diseases research.
Dr. Craig Kundrot
Dr. Craig Kundrot
Director of the Space Life and Physical Sciences Research
Dr. Craig Kundrot is the Director of the Space Life and Physical Sciences Research and Applications (SLPSRA) Division in NASA’s Human Exploration and Operations Missions Directorate. Craig has a Bachelor’s degree from Northwestern University and a doctorate from Yale University.
He is an erstwhile structural biologist who studied protein and RNA structure-function relationships using x-crystallography as a faculty member at the University of Colorado. He joined NASA’s biotechnology program in 1998 at Marshall Space Flight Center as a senior scientist before assuming science management positions for biotechnology and materials science. In 2006, he moved to the Human Research Program at NASA’s Johnson Space Center where he served as the Deputy Chief Scientist and as the first Mission Scientist for the HRP’s Twins Study.
He also served as Chair of the Institutional Review Board at NASA Johnson Space Center helping formulate NASA’s genetic research policy for astronauts. In 2015, Dr. Kundrot became the Life Sciences Lead in the Office of the Chief Scientist at NASA Headquarters to coordinate life science research in astrobiology, human research, planetary protection and space biology within NASA and with other organizations. In 2016, Dr. Kundrot became the SLPSRA Director.
Dr. Lee Swem
Dr. Lee Swem
Senior Vice President and Chief Scientific Officer at Achaogen
Lee Swem is Senior Vice President and Chief Scientific Officer at Achaogen. Prior to this position, he served as the Vice President, Head of Research and Director of the Therapeutic Antibody Program at Achaogen, where he developed a state-of- the-art antibody discovery platform to rapidly identify rare functional antibodies to treat serious human infectious diseases.
Before joining Achaogen, Lee spent 4.5 years as a Scientist in the Department of Infectious Disease at Genentech. During his tenure at Genentech, he developed the anti-influenza A program, the anti-influenza B program, and began a small molecule anti-bacterial program. Under his leadership, the anti-influenza team established an innovative human B cell enrichment and cloning technique to discover rare functional antibodies. This work led to the discovery of a broadly neutralizing anti-influenza A antibody, which was transitioned into development as a first and best in class treatment for severe influenza A infections.
Lee also led the identification and development of a broadly neutralizing influenza B antibody. This molecule was transitioned to development as a treatment for severe influenza B infections. Prior to working at Genentech, Lee worked with Dr. Bonnie Bassler at Princeton University, where he successfully carried out multiple high-throughput screens to identify small molecule inhibitors of bacterial virulence cascades.
Lee received his Ph.D from Indiana University. Lee has authored an IND and over 25 patents and publications.
Douglas W. Bryce
Douglas W. Bryce
Joint Program Executive Office for Chemical and Biological Defense
Mr. Douglas W. Bryce was designated the Joint Program Executive Officer for Chemical and Biological Defense (JPEO-CBD) on 22 October 2015. As the JPEO-CBD, he has materiel acquisition decision authority for the services on chemical and biological defense equipment.
He provides acquisition management and professional leadership on complex issues related to joint service chemical and biological defense acquisition programs. He plans, directs, manages, coordinates the JPEO-CBD’s mission and is responsible for the development, acquisition, distribution, and deployment of highly specialized and dynamic joint chemical and biological defense devices, as well as medical diagnostic systems, drugs, and vaccines.